2013
DOI: 10.1016/j.bbrc.2013.10.117
|View full text |Cite
|
Sign up to set email alerts
|

Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
29
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 34 publications
(29 citation statements)
references
References 33 publications
0
29
0
Order By: Relevance
“…55 Finally, ATG4B is an emerging target for treatment of various cancers, and inhibitors are being actively developed. 56 If the above speculations prove correct, they counsel caution in the use of such compounds, as the resulting increase in intracellular proLC3 may increase susceptibility to RNA virus infections.…”
Section: Discussionmentioning
confidence: 99%
“…55 Finally, ATG4B is an emerging target for treatment of various cancers, and inhibitors are being actively developed. 56 If the above speculations prove correct, they counsel caution in the use of such compounds, as the resulting increase in intracellular proLC3 may increase susceptibility to RNA virus infections.…”
Section: Discussionmentioning
confidence: 99%
“…However, the role of ATG4 proteases in most diseases is context dependent, and the consequences of their modulation could differ greatly. For example, it has been suggested that changes in the expression of ATG4B in prostate cancer could either amplify the action of both chemotherapy and radiotherapy or contribute to the development of treatment resistance (120). Furthermore, inhibition of ATG4 proteases in radiation therapies sensitizes resistant carcinoma cells in most cases, although it also promotes resistance in some conditions (121), demonstrating the importance of a more comprehensive understanding of ATG4 function.…”
Section: Therapeutic Options Targeting Atg4 Proteasesmentioning
confidence: 99%
“…There is genetic proof of principal that loss of ATG7 suppresses tumorigenesis (5), and an inhibitor might be expected to do the same. Over-expression of a dominant-negative ATG4b can either increase toxicity or promote resistance to cytotoxic drugs, so the situation where an inhibitor would be useful requires further investigation (75). …”
Section: Introductionmentioning
confidence: 99%